Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, presenting limited therapeutic options and a grim prognosis due to its aggressive nature. Despite ongoing exploration of various combination therapies, a standardized treatment approach after the first-line treatment pr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaoying Li, Chaoxin Xiao, Ruizhen Li, Pei Zhang, Heqi Yang, Dan Cao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-02-01
coleção:	Frontiers in Immunology
Assuntos:	pancreatic ductal adenocarcinoma tumor immune microenvironment tyrosine kinase inhibitor immune checkpoint inhibitors chemotherapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1326556/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!